Hypoparathyroidism: translating science from the laboratory to the clinic.

Long-acting PTH analogues in chronic hypoparathyroidism show sustained PTH receptor activation with reduced needs for active vitamin D and calcium supplements, improving individualized management.

• Why it matters: Chronic hypoparathyroidism causes hypocalcaemia and multidimensional quality-of-life impairment, creating a clinical need for better diagnosis and more physiological, real-time treatment strategies.
• What they did: This Review synthesizes advances across targeted genetic testing, parathyroid autoimmunity assays, point-of-care calcium monitoring, and therapies including palopegteriparatide, eneboparatide, canvuparatide, and calcilytics like encaleret.
• The result: Emerging diagnostic tools and receptor-targeted, long-acting, and regenerative approaches are reshaping hypoparathyroidism care, with calcilytics normalizing CaSR hyperactivation in autosomal dominant hypocalcaemia type 1 and supporting broader future use.

AI summary of the abstract · may contain errors · not medical advice · read the paper.